NCT04722835 Lung Macrophage Populations and Functions in Chronic Obstructive Pulmonary Disease (COPD)-Susceptible Smokers
| NCT ID | NCT04722835 |
| Status | Recruiting |
| Phase | — |
| Sponsor | University of California, San Francisco |
| Condition | Copd |
| Study Type | OBSERVATIONAL |
| Enrollment | 40 participants |
| Start Date | 2021-03-01 |
| Primary Completion | 2030-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 40 participants in total. It began in 2021-03-01 with a primary completion date of 2030-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous disease that affects only a fraction of those who smoke tobacco. The origin of this variability in susceptibility to develop COPD is unclear, but understanding its underlying biology has important implications for our ability to design suitable preventative and therapeutic strategies for its management. This Department of Defense (DOD) discovery research proposes to develop methodologies and generate preliminary data needed to lay the foundation for a large study that would investigate the underlying biological susceptibility of those who smoke tobacco to develop COPD.
Eligibility Criteria
Inclusion Criteria: * Ages between 40 to 75 years old. * History of at least 20 pack-years of smoking. * No diagnosis of COPD or asthma. * No spirometric evidence of airflow obstruction as determined by FEV1/FVC ratio ≥0.7. * FEV1 and FVC \>lower limit of normal. * Less than 1 pack-year history of tobacco smoking and no tobacco use within the past 12 months. * Subjects will be divided into two groups by their RV/TLC: Normal RV/TLC Group: • Plethysmographic RV/TLC equal or less than lower limit of normal. Abnormal RV/TLC Group: • Plethysmographic RV/TLC higher than lower limit of normal. Exclusion Criteria: * Any history of IV drug use or inhalation of recreational drugs other than marijuana: A- within the past 20 years. B- more than 100 times IV drug usage. C- longer than 1 year usage. * Marijuana use \>400 joints in lifetime or any within past 6 months. * Inability to walk briskly, run on treadmill, or pedal on ergometer to perform the study-required exercise level. * Pregnant/breast feeding. * Serious and active heart conditions- defined by stable or unstable angina, recent myocardial infarction (within the last 2 years), active congestive heart failure, ischemic cardiomyopathy. * Liver cirrhosis. * History of chronic active Hepatitis B or C.
Contact & Investigator
Mehrdad Arjomandi, MD
PRINCIPAL INVESTIGATOR
University of California, San Francisco
Frequently Asked Questions
Who can join the NCT04722835 clinical trial?
This trial is open to participants of all sexes, aged 40 Years or older, up to 75 Years, studying Copd. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT04722835 currently recruiting?
Yes, NCT04722835 is actively recruiting participants. Contact the research team at yorusaliem.abrham@ucsf.edu for enrollment information.
Where is the NCT04722835 trial being conducted?
This trial is being conducted at San Francisco, United States, San Francisco, United States, San Francisco, United States.
Who is sponsoring the NCT04722835 clinical trial?
NCT04722835 is sponsored by University of California, San Francisco. The principal investigator is Mehrdad Arjomandi, MD at University of California, San Francisco. The trial plans to enroll 40 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.